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Abstract
Background: Clenbuterol, a beta2-adrenergic receptor agonist, is used therapeutically to treat respiratory conditions
in the horse. However, by virtue of its mechanism of action it has been suggested that clenbuterol may also have
repartitioning affects in horses and as such the potential to affect performance. Clenbuterol decreases the percent fat
and increases fat-free mass following high dose administration in combination with intense exercise in horses. In the
current study, microarray analysis and real-time PCR were used to study the temporal effects of low and high dose
chronic clenbuterol administration on differential gene expression of several skeletal muscle myosin heavy chains,
genes involved in lipid metabolism and the β2-adrenergic receptor. The effect of clenbuterol administration on
differential gene expression has not been previously reported in the horse, therefore the primary objective of the
current study was to describe clenbuterol-induced temporal changes in gene expression following chronic oral
administration of clenbuterol at both high and low doses.
Results: Steady state clenbuterol concentrations were achieved at approximately 50 h post administration of the first
dose for the low dose regimen and at approximately 18–19 days (10 days post administration of 3.2 μg/kg) for the
escalating dosing regimen. Following chronic administration of the low dose (0.8 μg/kg BID) of clenbuterol, a total of
114 genes were differentially expressed, however, none of these changes were found to be significant following FDR
adjustment of the p-values. A total of 7,093 genes were differentially expressed with 3,623 genes up regulated and
3,470 genes down regulated following chronic high dose administration. Of the genes selected for further study by
real-time PCR, down-regulation of genes encoding myosin heavy chains 2 and 7, steroyl CoA desaturase and the
β2-adrenergic receptor were noted. For most genes, expression levels returned towards baseline levels following
cessation of drug administration.
Conclusion: This study showed no evidence of modified gene expression following chronic low dose administration
of clenbuterol to horses. However, following chronic administration of high doses of clenbuterol alterations
were noted in transcripts encoding various myosin heavy chains, lipid metabolizing enzymes and the
β2-adrenergic receptor.
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Background
Clenbuterol is a β2-adrenergic receptor agonist that is
labeled for use in the management of horses affected
with airway obstruction. Clenbuterol, a moderately se-
lective β2-adrenergic receptor agonist, causes relaxation
of airway smooth muscle by binding to the receptor and
activating adenylyl cyclase. Activation of adenylyl cyclase
leads to an increase in intracellular concentrations of
cyclic adenosine monophosphate (cAMP) and ultimately
activation of protein kinase A (PKA). In the airways this
inhibits smooth muscle contraction by opening K+ chan-
nels and down-regulating myosin light chain kinase
activity [1].
β2-adrenergic agonists are also known to promote lip-
olysis and increase muscle mass in many species [2–8].
This repartitioning effect and improvement in muscle
growth efficiency has led to the addition of β2-adrenergic
agonists such as ractopamine and zilpaterol to feed prod-
ucts for production animals. While not approved for use
as a growth-promoting agent, by virtue of its mechanism
of action, clenbuterol when administered at high doses
has been shown to have similar repartitioning effects in
many species [2, 4–7]. Since clenbuterol is an approved
therapeutic medication that is commonly used in race-
horses, regulators have expressed concern regarding its
potential to alter body composition in such a way as to
affect performance. Supporting this concern are reports of
decreases in the percent fat and increases in fat-free mass
following high dose clenbuterol administration (2.4 μg/kg
BID) in horses when combined with intense exercise [5].
However, it should be noted that although changes in
body mass have been documented in many species, per-
formance is not necessarily improved and in some cases
may be hindered [4, 9, 10].
Increases in myofibrillar and structural proteins
following clenbuterol administration have been well doc-
umented for several years [2–8]. More recently investi-
gators have used gene expression analysis techniques
including DNA microarray and qRT-PCR to elucidate
the underlying mechanism for these changes [11, 12].
To date the molecular effects of clenbuterol administra-
tion on gene expression have been described in produc-
tion animals and laboratory animal species [11, 12].
Spurlock and colleagues [11] demonstrated changes in
the mRNA abundance of multiple genes associated with
myogenic differentiation in mice following clenbuterol
administration. Increases in expression levels of lipid
metabolism related genes were demonstrated in pigs
following clenbuterol administration [12]. Investigators
speculated that one of these genes, apoR, might be
critical in reducing fat accumulation [12].
While the effect of high dose clenbuterol on skeletal
muscle fiber thickness in the horse has been assessed
[6], there are no studies assessing the effects of
clenbuterol at the molecular level in this species. There-
fore, in the current study we chose to use DNA technol-
ogy to assess the changes in skeletal muscle gene
expression following high dose administration of clenbu-
terol to horses. Furthermore, studies describing muscle
hypertrophy in horses have utilized high doses of the
compound [5, 6] and although clenbuterol is labeled for
use at doses as high as 3.2 μg/kg twice a day (BID), a
more common therapeutic dosing regimen in perform-
ance horses in the United States is chronic low dose
(0.8 μg/kg, BID) administration. Therefore, the primary
objective of the current study was to describe clenbuterol-
induced temporal changes in gene expression following
chronic oral administration of clenbuterol at both high
and low doses. We hypothesized that clenbuterol would
affect skeletal muscle gene expression (increased or de-
creased depending on the gene), relative to baseline levels,
in the horse in a dose dependent manner.
Methods
Animals, clenbuterol treatment and sampling
Twenty-eight healthy, exercised adult Thoroughbred horses
(11 mares and 17 geldings; weight range of 470.7 ± 25.0 kg;
age range of 2–6 years) were studied. Horses used in this
study were a combination of University and client owned
horses. This study was approved by the Institutional
Animal Care and Use Committee (University and client
owned horses) and the Clinical Trials Committee of the
University of California, Davis (client owned horses). For
client owned horses, written consent was obtained for par-
ticipation in the study. Prior to and throughout the course
of the study, horses were exercised five days a week. The
general exercise protocol was meant to simulate the
strenuous exercise of race training. The exercise regimen
for these horses consists of three days per week on an
Equineciser (Centaur Horse Walkers Inc, Mira Loma, CA,
USA) (5 min at walk; 30 min trot; 5 min walk) and two
days per week on a high speed treadmill (Mustang 2200,
Graber AG, Switzerland; Day 1: 5 min @1.6 m/s; 5 min @
4 m/s; 5 min @ 7 m/s; 5 min @ 1.6 m/s all at 6 % incline.
Day 2: 3 min @ 1.6 m/s; 4 min @ 4.0 m/s; 2 min @ 7.0 m/s;
2 min @ 11.0 m/s and 5 min @1.6 m/s all at 3 % incline).
All horses were subject to regular fitness testing, including
weekly heart rate measurements and calculation of V200
(running velocity that elicited a heart rate 200 bpm) and
monthly measurements of end run plasma lactate concen-
trations, as a means by which to ensure that the fitness
level of the horses used in this study were as comparable
as possible to the average racehorse.
Prior to commencement of the study, all horses were
determined healthy and free of cardiovascular diseases by
physical examination, complete blood count and a serum
biochemistry panel that included aspartate aminotransfer-
ase, creatinine phosphokinase, alkaline phosphatase, total
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bilirubin, sorbital dehydrogenase, blood urea nitrogen and
creatinine. Horses did not receive any other medications
for at least two weeks prior to conducting this study.
Twenty-two of the horses received 0.8 μg/kg clenbu-
terol (Ventipulmin®, Boehringer Ingelheim Vetmedica
Inc, St Joseph, MO) PO BID for 30 days and an add-
itional 6 horses received the escalating dosing protocol as
described on the manufacturer label for non-responders
(0.8 μg/kg, BID × 3 days; 1.6 μg/kg, BID × 3 days; 2.4 μg/kg,
BID × 3 days; 3.2 μg/kg, BID for 21 days).
Blood samples were collected at time 0 and at 15, 30,
and 45 min, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8 and 12 h
post administration of the first dose and last dose and
18, 24, 36, 48, 60, 72, 84, 96, 108 and 120 h post admin-
istration of the last dose. Additionally blood samples
were collected every 12 h (immediately prior to adminis-
tration of each dose (trough concentrations)) throughout
the 30-day dosing period. Blood samples were collected
by direct venipuncture into EDTA blood tubes (Kendall/
Tyco Healthcare, Mansfield MA) and were centrifuged at
3000 × g for 10 min. Plasma was immediately transferred
into storage cryovials (Phenix Research Products, Chandler,
NC) and stored at −20 ° C until analysis. Drug concentra-
tions were measured by Liquid Chromatography tandem
Mass Spectrometry as described previously [13].
Muscle biopsy samples were collected one day prior to
administration of the first dose of clenbuterol. Add-
itional samples were collected at 48 h and on days 7, 14,
and 28 post administration of the first dose. A final sam-
ple was collected one-week post administration of the
final dose (35 days post administration of the first dose).
Muscle biopsies were collected at the same time on each
sampling occasion which was approximately 3–4 h post
feeding. Horses were not exercised on the day that
muscle biopsy samples were collected. For sample
collection, horses were sedated with a combination of
xylazine (Lloyd Inc, Shenandoah, IA) and butorphanol
(Zoetis, Florham Park, NJ). Lidocaine (Aspen Veterinary
Resources Ltd, Liberty MO) was administered subcuta-
neously over the gluteus muscle. A small area over the
superficial gluteal muscle was aseptically prepped and a
Bergstrom biopsy needle (Dixons Surgical Instruments,
Wickford, Essex) used to collect a small sample
(approximately 1 g of tissue). The tissue was transferred
to a cryovial containing RNAlater (Qiagen Inc, Valencia,
CA) and stored at −20 ° C until processed.
RNA extraction and quality assessment
Muscle biopsy samples were placed in 600 μl of lysis
buffer, contaning 2-β- mercaptoethanol (Qiagen Inc,
Valencia, CA). The tissue sample was then transferred to
MagNa Green Beads tubes (Roche Diagnostics, Mannhein,
Germany). Homogenization was performed using a
MagNaLyse (Roche Diagnostics, Mannhein, Germany) at
6000 rpm for 30 s followed by a 1.0 min cool down period.
Homogenization intervals were continued until pieces of
muscle were no longer visible (≤3 times). Total RNA was
purified using an miRNeasy Mini kit (RNeasy Mini,
Qiagen Inc, Valencia, CA) and following the manufac-
turer’s instructions. Total RNA integrity was assessed using
the Experion Automated Electrophoresis System (Bio-rad,
Hercules, CA). Only RNA samples with RIN ≥ 8 and 260/
280 ratios between 1.7 and 2.1 were used [14, 15].
Microarray analysis
Equine specific microarrays (EquGene-1.0-st; Affymetrix,
Santa Clara, CA), containing 504,603 probes represent-
ing 30,559 well-characterized genes were used.
To reduce biological noise as a result of genetic vari-
ability, each horse (5 horses for low dose administration
and 4 horses for the escalating dosing regimen) was ana-
lyzed separately and served as their own control for
comparison of baseline samples to day 14 (low dose ad-
ministration) or day 28 (escalating dose regimen). Five
biological replicates per time point were tested. Purified
total RNA (5 μg) was used for cDNA synthesis in ac-
cordance with the Ambion® WT Expression assay kit
(Affymetrix, Santa Clara, CA) manufacturer’s protocol.
In vitro transcription was used to incorporate biotin la-
bels using the GeneChip® WT Terminal Labeling system
(Affymetrix, Santa Clara, CA) and samples hybridized to
the Equine microarray. Arrays were washed and stained
on a Fluidics Station 450 (Affymetrix, Santa Clara, CA)
and scanned on a GeneChip Scanner 3000 (Affymetrix,
Santa Clara, CA) in accordance with manufacturer’s
protocols.
The microarrays were evaluated for differential gene
expression using Transcriptome Analysis Console (TAC)
and for hybridization quality control using Expression
Console Software (Affymetrix, Santa Clara, CA). In brief,
a total of five Cell Intensity Files were generated per
time point, uploaded and normalized under the fol-
lowing conditions: PM (perfect match)-only as a PM
intensity adjustment and the Robust Multichip Analysis
(RMA) quantification method. For evaluation of the as-
says performance the number of differentially expressed
(DE) genes detected between baseline and day 14 (low
dose administration) or day 28 (escalating dose regimen)
were assessed. Based on the TAC software user’s manual,
genes with mean transformed ratios significantly less
than −2 and larger than +2 were considered significantly
regulated. Significant DE genes were selected by filtering
the genes using an ANOVA (p value < 0.05). A Pearson’s
correlation coefficient was used to calculate linear
dependence between time point and baseline samples to
evaluate the correlation coefficient, where 1 was a posi-
tive correlation and 0 was no correlation. For each pro-
beset, expression at day 14 (low dose administration) or
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day 28 (escalating dose regimen) was compared to
expression at baseline in the same horse using a paired
t-test. Fold changes and their confidence intervals were
calculated by exponentiating (base 2) the mean within-
horse difference in expression for each gene and the as-
sociated t confidence intervals. P-values were adjusted
for multiple testing using the False Discovery Rate (FDR)
method of Benjamini and Hochberg [16]. Analyses were
conducted using the statistical software environment R,
version 3.0.2 (R Core Team, 2013). Gene Ontology bio-
logical process of differently expressed genes of interest was
performed using the most recent Database for Annotation,
Visualization and Integrated Discovery (DAVID) 6.8 Beta
(https://david-d.ncifcrf.gov/) with the Entrez Gene ID as
the primary identifier and Equus Caballus as the species.
Quantification of mRNAs using Taqman low density
arrays (TLDA)
Genes that showed significant changes in expression
(greatest fold change and statistical significance) follow-
ing microarray analysis as well as those that have previ-
ously been reported to be affected by clenbuterol
administration, were chosen as candidate genes for fur-
ther study. Microarray data were validated by measuring
the levels of specific mRNA in muscle biopsy samples at
each time point post clenbuterol administration vs. base-
line via Taqman Low Density Arrays (TLDA; Affymetrix,
Santa Clara, CA) which are pre-loaded 384 well RT-PCR
microfluidic cards.
RNA was diluted to a concentration of 2 ng/μl for cDNA
conversion using the QuantiTect Reverse Transcription Kit
(Qiagen Inc., Valencia, CA). cDNA was then combined
with Taqman Universal Mastermix (Affymetrix, Santa
Clara, CA) at a final concentration of 2X and then 100ul of
each sample loaded onto the TLDA card.
Primers for candidate genes were designed and manu-
factured by Life Technologies (Affymetrix, Santa Clara,
CA). Reference or “housekeeping” genes were used to
evaluate the effect of RNA integrity on the array and
qRT-PCR performance. Based on stability across all
samples studied (TaqMan Protocol [17]) equine beta 2
microglobulin (β2M) was used as the endogenous control
gene to normalize the qRT-PCR data while human 18 s
(hs18s) was used as an internal manufacturing control.
Each sample was run in quadruplicate with 10 candidate
genes per card. The TLDA cards were then run on a
QuantStudio™ 12 K Flex Software v1.2.2 (Affymetrix, Santa
Clara, CA). Analysis was performed using ExpressionSuite
Software 1.0.3 using Singleplex analysis (Affymetrix, Santa
Clara, CA).
Statistical analyses using commercially available soft-
ware (Stata/IC 13.1, StataCorp LP, College Station, TX)
were performed to assess significant differences in ex-
pression (fold change) between baseline and each time
point as well as between the different time points post
clenbuterol treatment. Data was analyzed using a mixed
effects analysis of variance, with the horse treated as a
random effect, and with time as fixed effects. Post-hoc
comparisons were performed with a Bonferonni multiple-
comparison adjustment to preserve a nominal significance
level of 0.05.
Results
Plasma clenbuterol concentrations
The average clenbuterol plasma concentration over
time-curves following chronic low dose and escalating
dose administrations are depicted in Fig. 1a, b, respect-
ively. Clenbuterol plasma concentrations were below de-
tectable levels by day 7 post administration of the final
dose in all 22 horses studied at the low dose and below
the LOQ of the assay by day 7 in 5/6 horses receiving
the escalating dosing protocol. The terminal elimination
half-life was 10.4 ± 4.4 h (mean ± SD) following chronic
low dose administration and 46.2 ± 8.37 h (mean ± SD)
following administration of the last dose (3.2 μg/kg) of
the escalating dosing protocol. Steady state concentra-
tions were achieved at approximately 50 h post adminis-
tration of the first dose for the low dose regimen and at
approximately 18–19 days (10 days post administration
of 3.2 μg/kg) for the escalating dosing regimen.
CDNA microarray analysis
Equine specific microarrays containing expression profil-
ing of 25,923 well-characterized genes were utilized. The
data has been deposited in the NCBI’s Gene Expression
Omnibus (GEO) [18] and are accessible through GEO
series accession number GSE79559. Baseline samples
collected the day prior to drug administration were com-
pared to those collected on day 14 (low dose administra-
tion) or day 28 (escalating dose regimen). Following
chronic administration of the low dose (0.8 μg/kg BID)
of clenbuterol, a total of 114 genes were DE, however,
none of these changes were found to be significant fol-
lowing FDR adjustment of the p-values. The volcano
plot of differentially abundant transcripts generated from
microarray analysis is depicted in Fig. 2a.
Following administration of the escalating dosing
protocol increases in expression levels of a number of
genes were noted. The volcano plot of differentially
abundant transcripts generated from microarray ana-
lysis is depicted in Fig. 2b. A total of 7,093 genes
were DE with 3,623 genes up regulated and 3,470
genes down regulated. Differentially expressed genes
were divided into groups according to their Gene
Ontology Biological Process descriptions (Table 1). A
total of 537 unique genes were identified and classified.
The largest number of genes were regulation of cellular
process related (247). Forty-three genes were actin-
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filament-based process related, 28 involved in muscle
system processes and 10 related to striated muscle
contraction.
Sixteen selected DE genes are listed in Table 2.
Based on the results of the microarray analysis (great-
est fold change and statistical significance) and
previously reported effects of clenbuterol on skeletal
muscle and lipid metabolism, 13 genes were selected
for further analysis to quantitate the change in ex-
pression levels, relative to baseline, at several time
points during the dosing period and following termin-
ation of clenbuterol administration.
Fig. 1 Mean ± SD plasma clenbuterol concentrations vs time following chronic (a) low dose and (b) high dose administration of (a)
0.8 μg/kg Ventipulmin® BID for 30 days to 22 racing fit Thoroughbred horses and (b) Ventipulmin® (0.8 μg/kg, BID for 3 days, 1.6 μg/kg,
BID for 3 days, 2.4 μg/kg, BID for 3 days and 3.2 μg/kg, BID for 21 days) to 6 racing fit Thoroughbred horses. Arrows indicate
administration of a new dose
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Fig. 2 (See legend on next page.)
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Quantification of mRNAs using Taqman low density
arrays (TLDA)
Genes selected for TLDA analysis included: β2-adrenergic
receptor (β2R), myosin heavy chain 2 (MYHC2A), myosin
heavy chain 7 (MYH7), myosin heavy chain 8 (MYH8),
myosin heavy chain 15 (MYHC15), myosin light chain
kinase (MYLK), muscle skeletal receptor tyrosine kinase
(MUSK), collagen type 3A1 (COL3A1), collagen type 1A1
(COL1A1), collagen type 1A2 (COL1A2), matrix metallo-
proteinase 13 (MMP13), steroyl CoA desaturase (SCD)
and lipoprotein lipase (LPL). Expression levels, relative to
baseline, at each time during and post clenbuterol admin-
istration for genes analyzed using TLDA are depicted
in Fig. 3.
Of the 13 genes selected for TLDA analysis, 7 showed
a similar significant change (up or down-regulation) in
expression as that demonstrated on microarray analysis.
While changes in expression were detected for the
remaining 6 genes (MYH8, MYLK, MUSK, COL3A1,
COL1A2, MMP13 and LPL) these were not deemed sta-
tistically significant.
MYH2A was significantly down-regulated, compared
to baseline, on days 7, 14 and 28 post clenbuterol ad-
ministration with transcript levels returning towards
normal on day 35 (7 days post administration of the final
dose). MYH7 was also down-regulated starting on day 7
and continuing through day 35. On day 7, transcript was
significantly different from baseline and 48 h and subse-
quent samples were significantly different from day 7
levels. On day 7, MYH15 was significantly different from
baseline and 48 h transcript levels and on days 14 and
28, it was significantly different from day 7. The only
collagen gene affected following clenbuterol administra-
tion was COL1A2 on days 14 (significantly different
from baseline transcript levels) and 28 (significantly
different from day 14). Although not significant, SCD
transcript levels first increased relative to baseline (48 h
and day 7). Starting with the day 14 sample and continu-
ing through the final time point (day 35), SCD transcripts
were significantly down-regulated compared to baseline.
The β2 adrenergic receptor was up-regulated, although
not significantly so at the first two time points (48 h and
day 7). Significant down-regulation of the β2R gene was
noted on days 14 (compared to 48 h), 28 (compared to
baseline, 48 h and day 7) and 35 (compared to day 28).
Discussion
Clenbuterol administration has been associated with
changes in body composition including alterations in lipid
metabolism and changes in skeletal muscle fibers [2–8].
Numerous studies have shown that these drug-induced al-
terations are a result of changes at the molecular level,
namely changes in mRNA expression [11, 12]. Alterations
in body composition, including a significant shift in the
myosin heavy chain protein profile [6] and alterations in
plasma leptin and adipopnectin concentrations [7] have
been reported following clenbuterol administration to
horses. However, to the best of the authors’ knowledge,
this is the first report to describe temporal alterations in
mRNA expression following clenbuterol administration to
horses, using 2 commonly used dosing regimens.
As a means of providing a global overview of genes
affected by clenbuterol administration, microarray ana-
lysis, comparing mRNA levels prior to drug administra-
tion to the levels at 2 weeks (low dose administration) or
4 weeks (escalating dose regimen) post drug administra-
tion was used. No significant changes in gene expression
were noted following administration of the chronic low
dose protocol (0.8 ug/kg BID × 30 days). Conversely,
(See figure on previous page.)
Fig. 2 Volcano plot of differentially abundant transcripts at 2 weeks following oral administration of 0.8 μg/kg Ventipulmin® BID for 30 days to 22
racing fit Thoroughbred horses and (b) 4 weeks following oral administration of Ventipulmin® (0.8 μg/kg, BID for 3 days, 1.6 μg/kg, BID for 3 days,
2.4 μg/kg, BID for 3 days and 3.2 μg/kg, BID for 21 days) to 6 racing fit Thoroughbred horses. Red and green dots represent genes that are
significantly down-regulated and up-regulated, respectively
Table 1 Differentially expressed genes of interest (p < 0.05)
categorized according to the Gene Ontology biological
process terms
Gene ontology biological process category Number of genes
Regulation of cellular process 247
Localization 177
Proteolysis 172
Regulation of development 125
Death 117
Morphogenesis 116
Cell Adhesion 99
Biological Adhesion 99
Intracellular Transport 95
Homeostasis 74
Membrane Organization 72
Cell Differentiation 71
Cell Communication 58
Actin-Filament Based Process 43
Muscle System Process 28
Response Stimulus 20
Striated Muscle Contraction 10
A total of 537 unique gene identifiers were identified and classified in
categories with a minimum of 6 members
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following high dose chronic administration, significant
changes were noted in genes coding for select myosin
heavy chain isoforms, proteins involved in fatty acid me-
tabolism and the β2 adrenergic receptor. The remainder
of this discussion pertains to the high dose (escalating
dosing) regimen.
Skeletal muscle fibers
Myosins are actin-based motor proteins that function in
the generation of mechanical force [19] and are respon-
sible for producing contraction in muscle cells. There
are a number of isoforms of myosin heavy chains and
fiber type is dependent on the isoform that is present.
Myosin heavy chains are encoded by a highly conserved
multi-gene family and include isoforms such as 2A, 2B
and 2X [19]. The MYH2B gene is not expressed in
equine skeletal muscle [20]. Myosin heavy chain 7 is
another member of the myosin family found primarily in
cardiac but also in skeletal muscle [21] and encoded by
the MYH7 gene.
Alterations in the skeletal muscle fiber profile have
been described following administration of β2 adren-
ergic agonists, including clenbuterol and ractopamine
[11, 12, 22, 23]. At the protein level, this most com-
monly involves a shift from the MYH1 to the MYH2A
and 2X fiber type [24–26]. In the current study, there was
not a significant change in either MYH1 or MYH2X gene
expression on microarray analysis, therefore, these genes
were not selected for further study. In a study similar to
the currently reported one, ractopamine was administered
to pigs, yielding similar results with respect to MYH1
expression [22]. An apparent lack of agreement between
expression of MYH transcripts and protein isoforms has
been described previously in horses and was attributed to
the presence of hybrid fibers [27]. Additionally, other
investigators have theorized that fibers that have more
than one MYH protein and only one transcript could be a
result of fibers converting to the type corresponding to
the expressed transcript [28–30].
A decrease in MYH2A protein levels has been demon-
strated in horses following administration of clenbuterol
[6]. Similarly, in the current study, MYH2A gene expres-
sion was significantly down regulated (relative to baseline).
This was first observed on day 7 and continued through-
out the dosing period with maximum effects on expres-
sion occurring on 28. This was also the time at which
steady state clenbuterol concentrations post the final dose
escalation, were achieved, suggesting a dose dependent
effect. MYH2A levels were not significantly different from
baseline at the last time point tested, which was 5 days
after termination of dosing, further supporting a dose
dependent effect.
Genes involved in lipid metabolism
SCD is responsible for converting fatty acids into mono-
unsaturated fatty acids in mammalian adipocytes [31].
Up-regulation of the SCD gene in skeletal muscle has
been associated with abnormal lipid partitioning and
Table 2 Selected differentially expressed genes utilizing an equine specific microarray following administration of an escalating
dosing regimen (0.8 μg/kg, BID × 3 days; 1.6 μg/kg, BID × 3 days; 2.4 μg/kg, BID × 3 days; 3.2 μg/kg, BID for 21 days) to 6 exercised
Thoroughbred research horses. For microarray analysis, baseline (pre-dose) transcript levels were compared to transcript levels on
day 28
Gene symbol Gene name Fold change P value (FDR corrected)
MYH2A Myosin Heavy Chain 2A, skeletal muscle −30.5 <0.001
MYH7 Myosin Heavy Chain 7, cardiac and skeletal 1.39 0.002
MYH8 Myosin Heavy Chain 8, skeletal muscle 1.86 0.014
MYH9 Myosin Heavy Chain 9, non-muscle −2.60 0.001
MYH10 Myosin Heavy Chain 10, non-muscle −1.31 0.028
MYH11 Myosin Heavy Chain 11, smooth muscle −2.24 0.033
MYH15 Myosin Heavy Chain 15 2.10 <0.001
ADRB2 Adrenoreceptor, beta 2 −4.0 0.001
COL1A1 Collagen, type 1, alpha 1 −1.8 0.019
IL1A Interleukin 1, alpha 3.42 <0.001
IL6 Interleukin 6 3.38 0.002
IL31RA Interleukin 31, receptor A 2.77 <0.001
DSC2 Desmocollin 2 2.95 0.001
PMP22 Peripheral myelin protein 22 −2.5 <0.001
PMPCA Peptidase alpha −2.64 <0.001
KRTAP20-2 Keratin associate protein 20-2 7.32 <0.001
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Fig. 3 (See legend on next page.)
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obesity in humans and lower levels of SCD with a leaner
body type [32]. β2 adrenergic agonists have demon-
strated effects on lipid metabolism [12], including down-
regulation of SCD. This has been demonstrated in pigs
following 4 weeks of treatment with ractopamine
(25 mg/kg BID; [12]). In the current study, SCD mRNA
expression decreased starting on day 14 and continued
until 7 days post clenbuterol administration (day 35).
This time course is highly suggestive of a dose-
dependent effect as no effects on SCD were observed
following chronic low dose administration (0.8 ug/kg
BID × 30 days). Furthermore, following administration
of the escalating non-responder dosing regimen, signifi-
cant effects were not observed until day 14, after signifi-
cant drug accumulation had occurred.
β2- adrenergic receptor
Chronic administration of β2-adrenergic agonists has been
associated with down-regulation of the β2-adrenergic re-
ceptor in humans [33] and horses [34]. In conjunction
with this down-regulation, a number of investigators have
noted a decrease in β2R mRNA [34]. Decreased levels of
β2R mRNA has been reported in fast twitch muscle fibers
in rats following clenbuterol administration [33, 35] and
in pigs following long-term ractopamine administration
[22]. In the current study, β2R mRNA levels were
unaffected following low dose clenbuterol administration,
however, following administration of the escalating dosing
protocol, mRNA levels decreased significantly by days 14
and 28. Abraham and colleagues [34] demonstrated a
down-regulation of β2-adrenergic receptors following
chronic clenbuterol administration and theorized that this
provided an explanation for variable sensitivity of horses
with chronic obstructive pulmonary disease to β2-
adrenergic agonists as well as the development of
tolerance with long term treatment. Similarly in the
current study, decreased β2RmRNA expression as a result
of high dose chronic clenbuterol administration may lead
to down-regulation of β2-adrenergic receptors and offer
an explanation for the decreased expression of MYH,
MYLK, MUSK, ACD and LPL. By day 35 (7 days post ter-
mination of drug administration), β2R levels had returned
towards baseline levels, presumably due to decreasing
concentrations of clenbuterol.
Conclusion
In the current study, we describe changes in gene
expression in skeletal muscle following chronic adminis-
tration of clenbuterol to horses. Changes in gene ex-
pression were not noted following administration of
therapeutic low doses, however, following chronic
administration of high doses of clenbuterol alterations
were noted in transcripts encoding various myosin heavy
chains, lipid metabolizing enzymes and the β2R.
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(MYLK) and skeletal muscle receptor tyrosine kinase (MUSK), c collagen type 1A1 (COL1A1), collagen type 1A2 (COL1A2) and collagen type 3A1
(COL3A1), d matrix metalloproteinase 13 (MMP13), e steroyl CoA desaturase (SCD) and lipoprotein lipase (LPL) and f β2-adrenergic receptor ((β2R)
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